HIV Vaccines

AIDS VACCINE TRIALS UNDER WAY OR RECENTLY COMPLETED
Manufacturer	Vaccine	Location	Clinical Status	Designator	Other Information (information derived mostly from NIAID-AVEG)	Links
Subunit Vaccines
VaxGen	gp120	U.S., Canada, Thailand, Netherlands	Phase I/II		Recombinant gp120 envelope (protein coat) antigens from two B clade viruses. These viruses are representative of the viruses circulating in North America, Western Europe, Australia, the Caribbean, parts of Thailand, and South America	Manufacturer
Chiron	gp120	Thailand, US	Clinical		NV 2-3 is a non-glycosylated, denatured polypeptide containing the entire primary sequence of the gp120 envelope protein of HIV-1. It is obtained from the SF-2 isolate of HIV and produced in genetically engineered yeast. The HIV SF-2 gp120 candidate vaccine is a recombinant product produced in genetically engineered CHO cells under the control of the cytomegalovirus (hCMV) immediate early - 1 (IE-1) promoter.
Pasteur Mérieux Connaught	gp160 expressed from vaccinia virus in baby hamster kidney cells	U.S.	PhaseI/II		Recombinant protein gp160MN/LAI-2 is an envelope glycoprotein from HIV-1 virus expressed by VV.TG.9150 vaccinia virus on BHK21 cells under the control of the vaccinia H5R promotor. Recombinant protein is produced by infected BHK21 cells, followed by a multistep purification process
Cel-Sci/British Biotech	p17	Europe	Phase I	Ty-VLP	An expression plasmid encoding the p1/p17/p24 fusion gene is introduced into yeast cells. The cells are grown to high cell density in a medium containing glucose. Expression of the fusion protein is then induced by adding galactose which switches on the production via a cascading promoter system.
Harmless virus with an HIV gene
Pasteur Mérieux Connaught	canarypox with HIV gp120 gene	U.S., France, Uganda	Phase I	ALVAC vCP125	Recombinant canarypox-HIV-1 MN gp160 virus. Produced by homologous recombination between the plasmid pC5HIVMNE and the genomic DNA of canarypox, thereby substituting the gp160 gene for the open reading frame C5. The gp160 gene is under the control of the vaccinia H6 promoter.
Pasteur Mérieux Connaught + Chiron	canarypox with various HIV genes gp120	U.S.		ALVAC vCP205	The recombinant canarypox-HIV-1 virus, is a second generation vaccine that can be used to induce a humoral and cellular response against several antigens. It expresses these products of HIV-1 genes: the gag gene expressing the gag p55-poly protein of the HIV-1 LAI strain; the protease gene, expressing the p15 protein of the HIV-1 LAI strain; a part of the env gene expressing the glycoprotein (gp) 120 of the HIV-1 MN strain, and the anchoring region of gp41, the transmembrane glycoprotein (TM) of the HIV-1 LAI strain.
Pasteur Mérieux Connaught + VaxGen	canarypox with various HIV genes gp120	U.S.		ALVAC vCP300	The recombinant canarypox-HIV-1 virus, is a second generation vaccine that can be used to induce a humoral and cellular response against several antigens. It expresses these products of HIV-1 genes: the gag gene expressing the gag p55-poly protein of the HIV-1 LAI strain; the protease gene, expressing the p15 protein of the HIV-1 LAI strain; a part of the env gene expressing the glycoprotein (gp) 120 of the HIV-1 MN strain, and the anchoring region of gp41, the transmembrane glycoprotein (TM) of the HIV-1 LAI strain: a part of the HIV-1 nef gene (LAI strain) gene encoding two peptides (9.1 and 3.3 kDa) containing multiple CTL epitopes; a part of the HIV-1 pol gene (LAI strain) encoding three peptides (5.5, 7.2 and 7.0 kDa) containing multiple CTL epitopes
Pasteur Mérieux Connaught	canarypox with various HIV genes gp120	US		ALVAC-HIV (vCP1433)	Modified recombinant canarypox virus expressing the products of the HIV-1 env, gag and the potion of the pol gene encoding the protease genes, and a synthetic polypeptide encompassing the known human CTL epitopes from the nef and pol gene products.
Pasteur Mérieux Connaught	canarypox with various HIV genes gp120	US		ALVAC-HIV (vCP1452)	Modified recombinant canarypox virus expressing the products of the HIV-1 env, gag and the pol gene encoding the protease, and a synthetic polypeptide encompassing several known human CTL epitopes from the nef and pol gene products.
Therion	vaccinia with HIV envelope gene	U.S.		TBC-3B	A live recombinant vaccinia-HIV-1 virus that expresses multiple genes of HIV-1. The parental strain used for the generation of this vaccine was purified from a licensed vaccine strain of vaccinia virus. The insertion of the HIV-1 (strain IIIB) env, gag and pol genes, each under the transcriptional direction of a vaccinia promoter element, into the genome of this parental virus has resulted in the generation of a multivalent recombinant virus that efficiently expresses fully processed, authentically configured HIV-1 polypeptides encoded by those genes. The vaccine elicits both humoral and cell mediated immune responses to the expressed polypeptides.
St. Jude Children's Research Hospital	23 HIV envelope proteins in 23 vaccinia vectors	Memphis, Tennessee			The incorporation of many envelope proteins into a multi-envelope AIDS vaccine allows recognition of a cross section of virus envelopes that have emerged in developing and developed regions of the world	St Judes
DNA Vaccines
Wyeth-Lederle	DNA vaccine with various HIV genes	U.S.		APL 400-047	This vaccine expresses the HIV type-1 core structural proteins, reverse transcriptase and integrase proteins. Both the reverse transcriptase and integrase proteins are partially deleted and non-functional. These genes are derived from the HIV-1 strain HXB2 and are inserted into the GENEVAX® DNA plasmid backbone.
Pasteur Mérieux Connaught + Wyeth-Lederle	canarypox with various HIV genes DNA vaccine	U.S.
Other
Pasteur Mérieux Connaught	lipopeptide	France
Univ. of Maryland + VaxGen	salmonella with gp120 gp120	U.S.			Attenuated Salmonella. typhi CVD 908 is a live vector expressing an engineered prokaryotic expression cassette that encodes HIV-1 gp120 or truncated gp120, resulting in secretion of recombinant gp120 into the cytoplasm or periplasmic compartment of the S. typhi vector